Imaging biomarkers and the role of neuroinflammation in neuropathic pain

Journal of Neuroimmune Pharmacology

Volumn 8, Issue 3, 2013, Pages 448-451

  Chang, Linda ^a   Cooper, Mark S ^b   Clark, Vincent P ^c  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Neuroimaging; Neuroinflammation; Neuropathic pain

Indexed keywords

BIOLOGICAL MARKER; INOSITOL; N ACETYLASPARTIC ACID; NALTREXONE;

BOLD SIGNAL; CLINICAL FEATURE; COMPLEX REGIONAL PAIN SYNDROME TYPE I; DISEASE ASSOCIATION; FIBROMYALGIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; LOW DRUG DOSE; MAGNETOENCEPHALOGRAPHY; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NEUROPATHIC PAIN; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETINA IMAGE; REVIEW; TELEMEDICINE; TRANSCRANIAL MAGNETIC STIMULATION; VISUAL FEEDBACK;

BIOLOGICAL MARKERS; DIAGNOSTIC IMAGING; EDUCATION; HUMANS; INFLAMMATION; NEURALGIA; NEURONS; NEW MEXICO; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84878791359     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-013-9457-5     Document Type: Review

References (12)

1. Bailey J, Nelson S, Lewis J, McCabe CS (2013) Imaging and clinical evidence of sensorimotor problems in CRPS: utilizing novel treatment approaches. J Neuroimmune Pharmacol. doi: 10.1007/s11481-012-9405-9
2. Barr MS, Farzan F, Davis KD, Fitzgerald PB, Daskalakis ZJ (2013) Measuring GABAergic inhibitory activity with TMS-EEG and its potential clinical application for chronic pain. J Neuroimmune Pharmacol. doi: 10.1007/s11481-012- 9383-y
3. Binkley KE (2013) Improving the diagnosis and treatment of CRPS: insights from a clinical immunologist's personal experience with an underrecognized neuroinflammatory disorder. J Neuroimmune Pharmacol. doi: 10.1007/s11481-012- 9376-x
4. Chang L, Munsaka S, Kraft-Terry S, Ernst T (2013) Magnetic resonance spectroscopy to assess neuroInflammation and neuropathic pain. J Neuroimmune Pharmacol
5. Chopra P, Cooper MS (2013) Treatment of complex regional pain syndrome using low-dose naltrexone. J Neuroimmune Pharmacol. doi: 10.1007/s11481-013- 9451-y
6. Cooper MS, Clark VP (2013) Neuroinflammation, neuroautoimmunity, and the co-morbidities of complex regional pain syndrome. J Neuroimmune Pharmacol. doi: 10.1007/s11481-012-9392-x
7. Davis KD, Moayedi M. (2013) Central mechanisms of pain revealed through functional and structural MRI. J Neuroimmune Pharmacol. doi: 10.1007/s11481-012-9386-8
8. Eyo UB, Dailey ME (2013) Microglia: key elements in neural development, plasticity, and pathology. J Neuroimmune Pharmacol. doi: 10.1007/s11481-013- 9434-z
9. Katzman JG (2013) Making connections: using telehealth to improve the diagnosis and treatment of complex regional pain syndrome, an underrecognized neuroinflammatory disorder. J Neuroimmune Pharmacol. doi: 10.1007/s11481-012- 9408-6
10. Linnman C, Becerra L, Borsook D (2013) Inflaming the brain: CRPS a model disease to understand neuroimmune interactions in chronic pain. J Neuroimmune Pharmacol. doi:10. 1007/s11481-012-9422-8
11. Saab C (2013) Visualizing the complex brain Dynamics of chronic pain. J Neuroimmune Pharmacol. doi: 10.1007/s11481-012-9378-8
12. Younger J, Mackey S (2009) Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med 10:663-672